CO-DIAGNOSTICS INC (CODX) Stock Price & Overview

NASDAQ:CODXUS1897632048

Current stock price

1.67 USD
0 (0%)
Last:

The current stock price of CODX is 1.67 USD. Today CODX is down by 0%. In the past month the price decreased by -17.33%. In the past year, price decreased by -88.75%.

CODX Key Statistics

52-Week Range1.35 - 46.5
Current CODX stock price positioned within its 52-week range.
1-Month Range1.35 - 1.95
Current CODX stock price positioned within its 1-month range.
Market Cap
6.012M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-22.54
Dividend Yield
N/A

CODX Stock Performance

Today
0%
1 Week
+7.05%
1 Month
-17.33%
3 Months
-84.98%
Longer-term
6 Months -83.12%
1 Year -88.75%
2 Years -95.03%
3 Years -96.24%
5 Years -99.42%
10 Years N/A

CODX Stock Chart

CO-DIAGNOSTICS INC / CODX Daily stock chart

CODX Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to CODX. When comparing the yearly performance of all stocks, CODX is a bad performer in the overall market: 99.29% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CODX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CODX. The financial health of CODX is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CODX Earnings

On March 31, 2026 CODX reported an EPS of -3.64 and a revenue of 264.00K. The company beat EPS expectations (0.87% surprise) and beat revenue expectations (105.42% surprise).

Next Earnings DateMay 6, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported-$3.64
Revenue Reported264K
EPS Surprise 0.87%
Revenue Surprise 105.42%

CODX Forecast & Estimates

7 analysts have analysed CODX and the average price target is 30.6 USD. This implies a price increase of 1732.34% is expected in the next year compared to the current price of 1.67.

For the next year, analysts expect an EPS growth of 45.02% and a revenue growth 18.89% for CODX


Analysts
Analysts45.71
Price Target30.6 (1732.34%)
EPS Next Y45.02%
Revenue Next Year18.89%

CODX Groups

Sector & Classification

Index Membership

CODX Financial Highlights

Over the last trailing twelve months CODX reported a non-GAAP Earnings per Share(EPS) of -22.54. The EPS increased by 33.51% compared to the year before.


Income Statements
Revenue(TTM)622.50K
Net Income(TTM)-46.90M
Industry RankSector Rank
PM (TTM) N/A
ROA -189.54%
ROE -227.33%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%66.3%
Sales Q2Q%77.18%
EPS 1Y (TTM)33.51%
Revenue 1Y (TTM)-84.1%

CODX Ownership

Ownership
Inst Owners6.91%
Shares3.60M
Float3.48M
Ins Owners3.31%
Short Float %4.85%
Short Ratio0.08

About CODX

Company Profile

CODX logo image Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 132 full-time employees. The company went IPO on 2017-07-12. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The firm also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. The company is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.

Company Info

IPO: 2017-07-12

CO-DIAGNOSTICS INC

2401 S. Foothill Dr. Suite D

Salt Lake City UTAH 84109 US

CEO: Dwight Egan

Employees: 132

CODX Company Website

CODX Investor Relations

Phone: 18014381036

CO-DIAGNOSTICS INC / CODX FAQ

What does CO-DIAGNOSTICS INC do?

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 132 full-time employees. The company went IPO on 2017-07-12. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The firm also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. The company is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.


What is the stock price of CO-DIAGNOSTICS INC today?

The current stock price of CODX is 1.67 USD.


What is the dividend status of CO-DIAGNOSTICS INC?

CODX does not pay a dividend.


What is the ChartMill rating of CO-DIAGNOSTICS INC stock?

CODX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the sector and industry classification for CO-DIAGNOSTICS INC?

CO-DIAGNOSTICS INC (CODX) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


What is the employee count for CODX stock?

CO-DIAGNOSTICS INC (CODX) currently has 132 employees.


Who owns CO-DIAGNOSTICS INC?

You can find the ownership structure of CO-DIAGNOSTICS INC (CODX) on the Ownership tab.